Table 3. Hazard ratios for cancer death in the Cox model adjusted in the prognosis groups in ns-TGCTs treated with cisplatin-based chemotherapy.
| Hazard ratio | 95% Confidence interval | P-value | |
|---|---|---|---|
|
Bivariate analysis | |||
|
ERCC1 IHC and CPS/non-CPSa | |||
| Positive and non-CPS | 17.06 | (6.24-46-62) | <0.001 |
| Negative and non-CPS | 20.75 | (8.06–53.42) | <0.001 |
| Negative and CPS |
1 |
|
|
|
IGCCCG classification | |||
| Good prognosis | 0.06 | (0.01–0.26) | <0.001 |
| Intermediate prognosis | 0.63 | (0.31–1.26) | 0.19 |
| Poor prognosis |
1 |
|
|
|
Multivariate analysis | |||
|
ERCC1 IHC and CPS/non-CPSa | |||
| Positive and non-CPS | 11.86 | (3.88–36.21) | <0.001 |
| Negative and non-CPS | 14.43 | (4.98–41.81) | <0.001 |
| Negative and CPS |
1 |
|
|
|
IGCCCG classification | |||
| Good prognosis | 0.38 | (0.07–2.05) | 0.26 |
| Intermediate prognosis | 0.92 | (0.45–1.91) | 0.84 |
| Poor prognosis | 1 | ||
Abbreviations: CPS=cisplatin sensitive; ERCC1= excision repair cross-complementation group 1; IGCCCG classification=International Germ Cell Cancer Collaborating Group classification; IHC=immunohistochemistry; non-CPS=non-cisplatin sensitive; ns-TGCTs=non-seminomatous testicular germ cell tumours.
a
The hazard ratio and confident interval values could not be estimated for the ERCC1-positive and CPS patients group because the deaths were not presented.